ArticleKidney & blood pressure research2026
Long Noncoding RNA MIR205HG Elevates FSTL1 Expression to Drive Calcium Oxalate Nephrolithiasis in vitro through Absorbing miR-5581-3p.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNephrolithiasis is a clinical entity with long-term course, facing rising global prevalence and recurrence rates. Long noncoding RNAs (LncRNAs) have emerged as regulators implicated in the progression of nephrolithiasis, yet the functional role of lncRNA MIR205HG remains poorly characterized. Our research attempted to investigate the function of the lncRNA MIR205HG in calcium oxalate (CaOx) nephrolithiasis and focus on its in-depth competitive endogenous RNA regulatory network.
methodsMIR205HG expression in the Randall's plaque tissues of CaOx nephrolithiasis patients and calcium oxalate monohydrate (COM)-stimulated HK2 cells was examined with GSE117518 dataset from GEO database and Reverse Transcription-Quantitative PCR (RT-qPCR). Cell Counting Kit-8 and flow cytometry assays separately estimated cell viability and apoptosis. DCFH-DA probe and Western blotting measured oxidative stress mediators. RT-qPCR also tested miR-5581-3p and follistatin-like protein 1 (FSTL1) expressions. A targeting relationship among MIR205HG, miR-5581-3p and FSTL1 was determined using bioinformatics software and luciferase reporter assays. Besides, cellular morphology was observed and cell adhesion was detected. Western blotting assessed epithelial-mesenchymal transition (EMT) markers.
resultsA total of 62 upregulated and 17 downregulated genes were identified. MIR205HG expression was elevated both in the Randall's plaque tissues of CaOx nephrolithiasis patients and COM-stimulated HK2 cells. MIR205HG silencing promoted the viability, inhibited the apoptosis, and ameliorated the oxidative stress in COM-induced HK2 cells. MIR205HG could sequester miR-5581-3p which directly targeted FSTL1. In addition to the impacts on FSTL1 expression, cell viability, apoptosis and oxidative stress, miR-5581-3p inhibitor could also restore the suppressive role of MIR205HG knockdown in the morphological changes, EMT and adhesion of COM-induced HK2 cells.
conclusionConclusively, lncRNA MIR205HG participated in the process of CaOx nephrolithiasis through mediating the miR-5581-3p/FSTL1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.